Skip to content

Study · Observational study · n = 143 · 2026

5 results

Weight Changes With Lower Doses of Semaglutide in Clinical Practice: Findings From the Chinese HARMONY Cohort.

Liu S, Cao B, Lin C, Chen W, Yang P, Luo Y, Xu J, Wang C

Diabetes, obesity & metabolism15 Jun 2026Cited by 1 (Europe PMC)

PMID42297751 (opens in a new tab)PMCIDPMC13449065 (opens in a new tab)DOI10.1111/dom.71004 (opens in a new tab)PepBankPUB-42297751
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In Chinese adults with obesity, lower-dose semaglutide gave a mean weight change of -7.3% at week 12 (6.7 kg).

    In plain wordsIn Chinese adults with obesity, people on lower-dose semaglutide lost on average 7.3% of body weight by week 12.

    Peptide
    Semaglutide
    Outcome
    DecreasePercent weight change at week 12
    Study

    n = 143

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5 or 1.0 mg once weekly · subcutaneous · 12 weeksAs given in this study (human).

    Measurements

    Mean percent weight change
    −7.3%
    week 12
    Mean absolute weight loss
    6.7 kg
    week 12

    Source sentences

    Summary
    Mean percent weight change was -7.3% at week 12 and -9.9% at week 24, corresponding to mean absolute weight losses of 6.7 and 9.1 kg, respectively.
    1 context sentence
    Summary · context
    Adults with obesity were enrolled from the HARMONY study, a real-world observational cohort in China.
  2. 02HumanObservational studyEfficacy outcome

    In Chinese adults with obesity, lower-dose semaglutide gave a mean weight change of -9.9% at week 24 (9.1 kg).

    In plain wordsIn Chinese adults with obesity, people on lower-dose semaglutide lost on average 9.9% of body weight by week 24.

    Peptide
    Semaglutide
    Outcome
    DecreasePercent weight change at week 24
    Study

    n = 113

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5 or 1.0 mg once weekly · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Mean percent weight change
    −9.9%
    week 24
    Mean absolute weight loss
    9.1 kg
    week 24

    Source sentences

    Summary
    Mean percent weight change was -7.3% at week 12 and -9.9% at week 24, corresponding to mean absolute weight losses of 6.7 and 9.1 kg, respectively.
    1 context sentence
    Summary · context
    Adults with obesity were enrolled from the HARMONY study, a real-world observational cohort in China.
  3. 03HumanObservational studyEfficacy outcome

    In Chinese adults with obesity, 76.1% of participants on lower-dose semaglutide achieved 5% weight loss or more by week 24.

    In plain wordsIn Chinese adults with obesity, 76.1% of people on lower-dose semaglutide lost at least 5% of body weight by week 24.

    Peptide
    Semaglutide
    Outcome
    DecreaseProportion with at least 5% weight loss at week 24
    Study

    n = 113

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5 or 1.0 mg once weekly · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Responders >=5% weight loss
    76.1%
    week 24

    Source sentences

    Summary
    By week 24, 76.1% of participants achieved 5% weight loss or more.
    1 context sentence
    Summary · context
    Adults with obesity were enrolled from the HARMONY study, a real-world observational cohort in China.
  4. 04HumanObservational studyEfficacy outcome

    In Chinese adults with obesity on lower-dose semaglutide, participants with type 2 diabetes lost less weight at week 24 than those without diabetes (-7.4% vs. -12.4%).

    In plain wordsIn Chinese adults with obesity on lower-dose semaglutide, people with type 2 diabetes lost less weight (7.4%) than those without (12.4%).

    Peptide
    Semaglutide
    Outcome
    MixedWeek 24 weight change by diabetes status
    Study

    n: not reported in source

    Comparator
    Participants without type 2 diabetes
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5 or 1.0 mg once weekly · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Weight change
    −7.4%
    with type 2 diabetes, week 24
    Weight change
    −12.4%
    without diabetes, week 24

    Source sentences

    Summary
    At week 24, participants with type 2 diabetes experienced lower weight change than those without diabetes (-7.4% vs. -12.4%, p < 0.001).
    1 context sentence
    Summary · context
    Adults with obesity were enrolled from the HARMONY study, a real-world observational cohort in China.
  5. 05HumanObservational studyEfficacy outcome

    In Chinese adults with obesity on lower-dose semaglutide, weight change was attenuated with baseline intrapancreatic fat deposition (-9.0%) compared with without it (-11.6%).

    In plain wordsIn Chinese adults with obesity on lower-dose semaglutide, people with fat in the pancreas lost less weight (9.0%) than those without (11.6%).

    Peptide
    Semaglutide
    Outcome
    MixedWeek 24 weight change by intrapancreatic fat deposition
    Study

    n: not reported in source

    Comparator
    Participants without baseline IPFD
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5 or 1.0 mg once weekly · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Weight change
    −9%
    with IPFD
    Weight change
    −11.6%
    without IPFD

    Source sentences

    Summary
    Weight loss also differed by baseline intrapancreatic fat deposition (IPFD) status, with attenuated weight change among patients with baseline IPFD (-9.0% with IPFD vs. -11.6% without IPFD, p = 0.043).
    1 context sentence
    Summary · context
    Adults with obesity were enrolled from the HARMONY study, a real-world observational cohort in China.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.